Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Biotechnology

Healthcare
$8.04 +1.97%

+$0.15 today

Market cap
$231.73M
Beta
2.35
P/E (TTM)
-2.7
EPS (TTM)
-$2.77
52W Low $5.85High $24.17

Volume 0.64M

Average 0.43M

ARCT Net Income

Bottom-line profit after all expenses, interest, and taxes.

Arcturus Therapeutics Holdings Inc.NASDAQ: ARCT

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$26.96M, compared with -$14.08M a year earlier. Trailing-twelve-month net income was -$78.67M.

Context

  • Net income amounted to 97.9% of revenue in FY2025, up 39.4 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 8 analysts of -$83.45M (-26.9%) for the fiscal year ending Dec 2026, a slowdown from the +18.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.96M+7.3% QoQ
Last fiscal yearDec 2025
-$65.78M+18.7% YoY
LTMMar 2026
-$78.67M-15.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-91.6%-208.7%-117.1 pp
1 year+18.7%-26.9%-45.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(65.78M) USD
Year-over-year change
+18.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ARCT compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.4% is the 5th highest of 10, against a peer median of -21.5%.
  • Net income amounts to 173.5% of revenue for ARCT, versus a peer median of 213.9%.
ARCT Competitors
Net Income for ARCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABUSArbutus Biopharma CorporationLTM Mar 2026$160.72M USD+309.9%—84.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.62M EUR-51.2%—339.4%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$48.88M USD-44.5%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-15.4%—173.5%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$84.93M USD+12.0%——
SLNSilence Therapeutics plcLTM Mar 2026-$85.17M USD——9243.0%
NVAXNovavax, Inc.LTM Mar 2026-$87.84M USD-118.3%—14.7%
VALNValneva SELTM Mar 2026-€138.03M EUR-71.7%—88.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$169.52M USD-21.5%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M USD+18.9%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.72M USD+23.4%—676.0%
Peer median (excluding ARCT) —-21.5%—213.9%

Competitors are the stored peer set for ARCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue12.36M205.76M157.75M138.39M67.22M
Cost of Revenue00003.03M
Gross Profit12.36M205.76M157.75M138.39M64.2M
Gross Margin100.0%100.0%100.0%100.0%95.5%
Research & Development173.76M147.75M192.13M195.16M112.21M
Selling, General & Admin41.45M46.07M52.87M52.82M46.08M
Operating Expenses215.21M193.58M235.95M234.06M139.15M
Depreciation & Amortization1.19M1.53M2.96M3.54M3.03M
EBITDA(199.81M)15.17M(24.17M)(77.4M)(62.76M)
EBITDA Margin-1616.7%7.4%-15.3%-55.9%-93.4%
Operating Income(202.85M)12.18M(78.21M)(95.67M)(74.96M)
Operating Margin-1641.3%5.9%-49.6%-69.1%-111.5%
Interest Income753K2.58M17.36M15.2M10.1M
Interest Expense2.67M3M767K00
Other Income / Expenses(822K)(1.53M)50.32M14.72M9.17M
Income Before Tax(203.67M)10.64M(27.89M)(80.95M)(65.78M)
Pre-Tax Margin-1648.0%5.2%-17.7%-58.5%-97.9%
Income Tax Expense01.3M1.84M(4K)0
Net Income(203.67M)9.35M(29.73M)(80.94M)(65.78M)
Net Margin-1648.0%4.5%-18.8%-58.5%-97.9%
EPS (Basic)(7.74)0.35(1.12)(3.00)(2.40)
EPS (Diluted)(7.74)0.35(1.12)(3.00)(2.40)
Weighted Avg Shares26.32M26.45M26.63M27M27.39M
Weighted Avg Shares (Diluted)26.32M27.09M26.63M27M27.39M

Arcturus Therapeutics Holdings Inc.

NASDAQ:ARCT

Intrinsic Alpha fair value

Locked

Current Price

$8.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.